NovoSculpt Named Best Body Contouring Clinic in the Tri-State Area for 2025
NovoSculpt has been honored as the Best Body Contouring Clinic in the Tri-State Area for 2025, solidifying its place as a leader in aesthetic care and body sculpting services.
Greenwich, CT, USA, June 15, 2025 -- NovoSculpt Celebrates Prestigious Recognition in Body Contouring Excellence
NovoSculpt proudly announces its recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025, a prestigious title that highlights the clinic's leadership in the rapidly growing field of body sculpting. The award emphasizes NovoSculpt's unwavering commitment to providing safe, effective, and customized solutions for those seeking transformative aesthetic results.
The recognition celebrates the clinic's dedication to patient care, innovative treatments, and personalized experiences, solidifying its position as the premier destination for body contouring in the region. NovoSculpt's approach to aesthetic medicine continues to disrupt traditional methods by focusing on minimally invasive treatments that provide lasting and natural results.
A Cutting-Edge Approach to Minimally Invasive Fat Removal
At the heart of NovoSculpt's success is its groundbreaking minimally invasive fat removal procedure, which allows patients to remove up to 11 pounds of localized fat in a single session. This innovative technique eliminates the need for scalpels, stitches, or general anesthesia, providing a safe and efficient solution for body sculpting. The procedure ensures a quick recovery time, with many patients resuming their daily activities in as little as 24 hours.
NovoSculpt's approach has proven to be a highly effective and patient-friendly alternative to traditional body contouring surgeries, enabling clients to achieve their desired body shape with minimal discomfort and downtime. This cutting-edge method continues to set NovoSculpt apart from other clinics in the Tri-State Area and positions the clinic as a trailblazer in the aesthetic industry.
Led by Expertise: Roberto Magana and a Skilled Team
NovoSculpt's success is driven by the vision and leadership of its founder and CEO, Roberto Magana, MBA. With over 15 years of experience in business strategy and leadership, Roberto's guidance has been pivotal in shaping the clinic's operations and ensuring the highest standards of care. Under his leadership, NovoSculpt has assembled a highly skilled team of medical professionals, including elite plastic surgeons and experienced staff, all of whom are dedicated to delivering exceptional results for every patient.
Roberto's commitment to operational excellence and patient satisfaction has been integral to the clinic's rapid growth and its recognition as the top body contouring clinic in the region. The clinic's collaboration with top-tier medical personnel ensures that each patient receives comprehensive care, with personalized treatment plans designed to meet their unique goals.
Building Trust with Transparent and Safe Practices
NovoSculpt's reputation is built on trust, transparency, and an unwavering focus on safety. The clinic operates within a QuadA-certified surgical suite, ensuring that every procedure is conducted in a safe and controlled environment. This certification is a reflection of the clinic's commitment to adhering to the highest medical and safety standards, providing clients with peace of mind throughout their body sculpting journey.
By prioritizing patient safety and comfort, NovoSculpt has earned a loyal clientele who often return to enhance additional areas or recommend the clinic to others—confident in its ability to deliver authentic, natural-looking results in a single session. The clinic's client-first approach has fostered strong, lasting relationships with patients, many of whom experience meaningful boosts in confidence and overall well-being.
Patient Satisfaction and Proven Results
NovoSculpt's minimally invasive approach consistently results in high patient satisfaction, with many clients experiencing impressive, natural-looking results after just one session. The clinic's innovative fat removal procedure has become the preferred choice for those seeking to reshape their bodies without undergoing more invasive surgical procedures.
In addition to fat removal, NovoSculpt offers a range of aesthetic treatments, including skin tightening with NovoTight™ and fat transfer for sculpted curves. These services are customized to each patient's specific needs, ensuring that every treatment plan aligns with their personal aesthetic vision. This personalized approach has contributed to NovoSculpt's reputation for excellence and its status as the top body contouring clinic in the Tri-State Area.
A Vision of Innovation and Care
NovoSculpt's success story is one of innovation, care, and patient-centric solutions. Founded by Roberto Magana, the clinic was created with the goal of offering a minimally invasive, highly effective approach to body contouring. Roberto's vision has led to the development of a clinic that fills the gaps in the market for minimally invasive, customized body sculpting treatments that deliver lasting results.
As the clinic continues to innovate and grow, NovoSculpt's commitment to patient satisfaction and exceptional care remains at the forefront. The clinic's ability to adapt to changing industry trends while maintaining its focus on personalized, safe, and effective treatments has allowed it to remain a leader in the body contouring field.
Celebrating Success: The 2025 Recognition
NovoSculpt's recognition as the Best Body Contouring Clinic in the Tri-State Area for 2025 is a monumental achievement that celebrates the clinic's leadership, innovation, and dedication to its patients. This award reaffirms NovoSculpt's position as a disruptor in the body contouring industry, offering cutting-edge treatments that prioritize both safety and transformative results.
As the clinic looks toward the future, it remains committed to setting the standard for excellence in aesthetic medicine. With a growing reputation for delivering remarkable body sculpting results, NovoSculpt continues to reshape the way individuals approach body contouring and aesthetic care.
About NovoSculpt
NovoSculpt is a leading body contouring clinic based in Greenwich, Connecticut, specializing in minimally invasive targeted fat removal, precision skin tightening, and aesthetic fat transfers—all performed to enhance body contours with immediate, visible results after a single session. No repeat treatments are necessary. Serving clients across the Tri-State Area and beyond, the clinic offers personalized body sculpting solutions tailored to each patient's goals. Founded by Roberto Magana, MBA, NovoSculpt combines cutting-edge technology, a skilled medical team, and a patient-centered approach to deliver safe, effective, and lasting results—without the need for traditional surgery.
Media Contact
Roberto Magana, MBA
Founder & CEO, NovoSculpt
Website: https://novosculpt.us
Email: [email protected]
Instagram: @novosculptus
Facebook: @NovoSculpt
TikTok: @novosculptus
LinkedIn: NovoSculpt
Contact Info:
Name: Roberto Magana
Email: Send Email
Organization: NovoSculpt
Website: https://novosculpt.us
Release ID: 89162338
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release, or if there is a need for a press release takedown, we urge you to notify us without delay at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond within 8 hours – ensuring swift resolution of identified issues or offering guidance on removal procedures. Delivering accurate and reliable information is fundamental to our mission.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
12 minutes ago
- CBS News
Chicago Cubs spotlight men's health for Father's Day
This Father's Day, the Chicago Cubs are reminding dads that when it comes to things health-related, sometimes it's not enough just to rub some dirt on it. The Cubs teamed up Sunday with Advocate Health Care to spotlight men's health. They hosted a Father's Day brunch for Advocate patients. Among those in attendance was 67-year-old prostate cancer survivor Clark Atwater. Atwater lost his own father to prostate cancer years ago. But he was still shocked when he himself got the diagnosis. "I didn't really have any symptoms, so a week before my yearly checkup, and gosh, here I am with a PSA elevated," Atwater said. "It's very important to get checked. Get your annual physicals, and ask for your PSA." Atwater is now in remission and feeling good. In fact, he is feeling so good that he threw out the ceremonial first pitch at Wrigley Field on Sunday, with his grandson by his side.
Yahoo
an hour ago
- Yahoo
This gene stops elephants from getting cancer – can it help human cancer research?
If you purchase an independently reviewed product or service through a link on our website, BGR may receive an affiliate commission. For decades, scientists have puzzled over a curious phenomenon called Peto's Paradox. In theory, large animals with long lifespans should develop cancer more often because they have more cells and more time for mutations to occur. Yet elephants, whales, and other giants of the animal world tend to get cancer far less often than humans do. Now, researchers are learning why. In a 2015 study, scientists discovered that elephants carry 19 extra copies of a powerful cancer-stopping gene called TP53. This gene acts as a genetic safeguard, detecting DNA damage and triggering cell death in potentially cancerous cells. For elephants, this enhanced genetic armor likely explains why they enjoy such low rates of cancer despite their size. Today's Top Deals Best deals: Tech, laptops, TVs, and more sales Best Ring Video Doorbell deals Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98 However, a new study has broadened this investigation to nearly 300 animal species. The researchers analyzed over 16,000 necropsy records and found that elephants are not alone. Many other species have evolved their own cancer resistance strategies. Some birds, bats, and even lizards showed remarkably low levels of cancer, while animals like ferrets and opossums had much higher rates. The study also shed light on how various traits influence cancer risk, and it isn't always related to how many copies of the cancer-stopping gene an animal has. Larger body mass was linked to a slightly higher chance of developing cancer, though not as strongly as expected. Longer gestation periods appeared to lower cancer risk, possibly because of enhanced cellular safeguards developed during extended fetal growth. However, the researchers found that animals in captivity did not show artificially high cancer rates due to living longer than they would in the wild. But what does this mean for human cancer research? Well, TP53 is already a key player in human cancer prevention and assessing cancer risks, but humans only have two copies of the gene. Learning how elephants and other species enhance their cancer defenses could lead to new cancer treatments that make human cells more resilient. The hope researchers have is that mimicking or boosting the effects of this cancer-stopping gene could help doctors develop therapies to reduce cancer incidence or slow its progression. Comparative oncology, the field that studies cancer across different species, is only just beginning to unlock these secrets. The next steps will involve exploring how other animals resist cancer and finding ways to translate those discoveries into medical advances for humans. More Top Deals Amazon gift card deals, offers & coupons 2025: Get $2,000+ free See the
Yahoo
an hour ago
- Yahoo
Statement from the Alzheimer's Drug Discovery Foundation on the Passing of ADDF Co-Founder and Co-Chairman Leonard A. Lauder
The Lauder Family's Vision and Catalytic Funding Through the ADDF Helped Seed and Transform the Alzheimer's Research Landscape NEW YORK, June 15, 2025 /PRNewswire/ -- It is with deep sorrow and profound admiration that the Alzheimer's Drug Discovery Foundation (ADDF) shares the passing of Co-Founder and Chairman, Leonard A. Lauder. A visionary philanthropist, cosmetics industry icon, and steadfast champion in the fight against Alzheimer's disease, Lauder's legacy is woven into the very fabric of the ADDF and the progress it has driven toward understanding, treating, and ultimately curing Alzheimer's. "Leonard Lauder was a once-in-a-generation visionary whose leadership, along with his brother Ronald, reshaped the Alzheimer's research landscape," said Dr. Howard Fillit, Co-Founder and Chief Science Officer of the ADDF. "From the very beginning, Leonard understood that Alzheimer's does not just impact the patient, it affects entire families. The Lauder family recognized the emotional, financial, and societal toll of this disease, and built the ADDF to accelerate the discovery and development of treatments that could change the trajectory for patients and their loved ones. Leonard's vision, generosity, and humanity spanned across his business acumen to his philanthropic endeavors, touching countless lives, and his legacy will endure in every breakthrough we help bring forward." Lauder and his brother, Ronald S. Lauder, co-founded the ADDF in 1998 with Dr. Fillit in honor of their mother, Estee Lauder's, battle with Alzheimer's. At a time when Alzheimer's research funding was sparse and interest from the private sector limited, the Lauder family recognized the urgent need for treatments and created a bold new venture philanthropy model to achieve this mission, combining the rigor of scientific research with the agility and entrepreneurialism of venture capital. For over more than 27 years, the Lauders' leadership helped shape the ADDF into the world's leading philanthropic funder of drug discovery and development research. Under the Lauders' guidance, the ADDF has: Invested more than $370 million into over 765 drug discovery programs across 21 countries Catalyzed more than $3 billion in follow-on funding from pharmaceutical companies, venture capital firms, and government agencies, helping to de-risk early-stage science and attract broader investment into Alzheimer's research Played a pivotal role in the development of the first biomarkers for Alzheimer's by providing early seed funding for Amyvid, the first FDA-approved PET scan for Alzheimer's; PrecivityAD, the first Alzheimer's blood test to market; and Lumipulse, the first Alzheimer's blood test to receive FDA approval Established the Diagnostics Accelerator (DxA) in partnership with Bill Gates and other visionary philanthropists to advance affordable, accessible diagnostic tools, a critical step toward earlier detection and intervention Advanced a diverse pipeline of treatments by pioneering the biology of aging approach, now central to the field, with over 70% of drugs targeting disease pathways such as inflammation, neuroprotection, vascular health, and synaptic function, paving the way for Alzheimer's to be treated with combination therapy and precision medicine, as in cancer Brought forward a precision prevention approach, combining lifestyle interventions and therapeutics to slow the progression or prevent the onset of Alzheimer's altogether Through all these achievements, Lauder and his family remained deeply committed to the ADDF's mission. "Leonard's impact on the ADDF, and on the field of Alzheimer's research more broadly, is immeasurable," said Mark Roithmayr, Chief Executive Officer of the ADDF. "He brought a sense of urgency to this work that pushed us all to do more and move faster. He believed that patients and families deserve better and he committed himself fully to building a world in which effective treatments are not only possible, but inevitable. His leadership, his generosity, and his humanity will continue to guide the ADDF's mission every day." Lauder's impact extended across business, culture, and philanthropy. Yet for those who worked alongside him at the ADDF, he will be remembered most for his compassion, clarity of purpose, and unwavering belief in progress. He understood that Alzheimer's is a deeply human and societal challenge, one affecting memory, identity, and dignity. The ADDF honors Lauder's legacy by reaffirming our commitment to conquer Alzheimer's for the millions of patients and families living with this devastating disease. About The Alzheimer's Drug Discovery Foundation (ADDF)Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $370 million to fund 765 Alzheimer's drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: View original content to download multimedia: SOURCE Alzheimer's Drug Discovery Foundation
